In PV and ET, MDS risk remains lower than AML risk but increases progressively with advancing attained age. Transformation to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in ...

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

Emergency hemopoiesis may maintain blood counts and a proinflammatory environment in MDS, AML, and ICUS. Altered neutrophil subset distributions in MDS and AML show diagnostic sensitivity, with ...

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...

Shorter-duration venetoclax may be as effective as longer-duration treatment in AML and MDS, with no significant impact on overall survival. The study included 53 patients, predominantly male, with a ...

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic ...

GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...

Evidence in real-world settings for multiple primary malignancies in prostate cancer: Comparison with single primary prostate cancers. Is increase in CME consumption associated with practice change in ...

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...